• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Johnson & Johnson’s Cordis bails on stents

Johnson & Johnson’s Cordis bails on stents

June 15, 2011 By MassDevice staff

Cordis

One of the biggest players in the coronary stent market is getting out of the business.

Cordis Corp., one of the medical device arms at Johnson & Johnson (NYSE:JNJ), announced the decision this morning, saying it will shut down development of its next-generation Nevo drug-eluting stent and stop making the Cypher DES line altogether by the end of 2011.

“Due to evolving market dynamics in the drug-eluting stent business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market,” Cordis group chair and worldwide chairman Seth Fischer said in prepared remarks.

Those dynamics include lower demand, pricing and reimbursement pressure and a more stringent regulatory environment, Cordis said, noting that "unlicensed competition from products that infringe Cordis patents, both owned and licensed" has cut into Cypher’s market share and "dampened the prospects" for commercializing the Nevo stent.

"At the same time, long-term data show some competitive DES offerings will adequately meet patients’ medical needs once Cordis exits the market," the company said in a press release.

In a separate release, J&J said it expects to log $500 million to $600 million in after-tax charges as a result of the plan, which will also mean layoffs for up to 1,000 workers. The move also means Cordis will shutter plants in Ireland and Puerto Rico and consolidate its research & development efforts in Fremont, Calif.

Cordis will focus its efforts on its BioSense Webster division, which makes electro-physiology products for cardiac applications and on its own, non-DES offerings in the cardiology and endovascular spaces. Those businesses threw off $1.9 billion in sales last year, excluding the drug-eluting stents operation, the company said.

Filed Under: Drug-Eluting Stents, News Well, Wall Street Beat Tagged With: Cordis Corp., Johnson and Johnson

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy